Cantel Medical Corp. (NYSE:CMD) EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $97.55, for a total value of $279,773.40. Following the completion of the sale, the executive vice president now directly owns 39,102 shares in the company, valued at $3,814,400.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Cantel Medical Corp. (NYSE CMD) opened at 97.05 on Tuesday. Cantel Medical Corp. has a 12 month low of $68.19 and a 12 month high of $99.83. The company has a market capitalization of $4.03 billion, a PE ratio of 56.75 and a beta of 1.25. The stock has a 50 day moving average price of $90.57 and a 200-day moving average price of $79.32.

Cantel Medical Corp. (NYSE:CMD) last announced its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.02. The company had revenue of $205.50 million during the quarter, compared to the consensus estimate of $200.32 million. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. Cantel Medical Corp.’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts forecast that Cantel Medical Corp. will post $2.37 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/24/cantel-medical-corp-cmd-evp-eric-w-nodiff-sells-2868-shares.html.

A number of analysts have recently commented on CMD shares. Zacks Investment Research raised Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research report on Tuesday, August 1st. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Wednesday, August 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Cantel Medical Corp. presently has a consensus rating of “Hold” and an average target price of $91.67.

A number of institutional investors and hedge funds have recently made changes to their positions in CMD. BlackRock Inc. acquired a new stake in Cantel Medical Corp. in the second quarter valued at approximately $376,271,000. Vanguard Group Inc. acquired a new stake in Cantel Medical Corp. in the second quarter valued at approximately $246,860,000. Neuberger Berman Group LLC acquired a new stake in Cantel Medical Corp. in the second quarter valued at approximately $96,236,000. Dimensional Fund Advisors LP acquired a new stake in Cantel Medical Corp. in the second quarter valued at approximately $75,756,000. Finally, Wells Fargo & Company MN acquired a new stake in Cantel Medical Corp. in the second quarter valued at approximately $75,715,000. Institutional investors own 83.82% of the company’s stock.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Insider Buying and Selling by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.